Syndecan-1 Is a Multifunctional Regulator of Myeloma Pathobiology: Control of Tumor Cell Survival, Growth, and Bone Cell Differentiation
Open Access
- 15 April 1998
- journal article
- Published by American Society of Hematology in Blood
- Vol. 91 (8) , 2679-2688
- https://doi.org/10.1182/blood.v91.8.2679.2679_2679_2688
Abstract
Multiple myeloma is characterized by an accumulation of malignant plasma cells in the bone marrow coupled with an altered balance of osteoclasts and osteoblasts, leading to lytic bone disease. Although some of the cytokines driving this process have been characterized, little is known about the negative regulators. We show that syndecan-1 (CD 138), a heparan sulfate proteoglycan, expressed on and actively shed from the surface of most myeloma cells, induces apoptosis and inhibits the growth of myeloma tumor cells and also mediates decreased osteoclast and increased osteoblast differentiation. The addition of intact purified syndecan-1 ectodomain (1 to 6 nmol/L) to myeloma cell lines in culture leads to induction of apoptosis and dose-dependent growth inhibition, with concurrent downregulation of cyclin D1. The addition of purified syndecan-1 in picomolar concentrations to bone marrow cells in culture leads to a dose-dependent decrease in osteoclastogenesis and a smaller increase in osteoblastogenesis. In contrast to the effect on myeloma cells, the effect of syndecan-1 on osteoclastogenesis only requires the syndecan-1 heparan sulfate chains and not the intact ectodomain, suggesting that syndecan's effect on myeloma and bone cells occurs through different mechanisms. When injected in severe combined immune deficient (scid) mice, control-transfected myeloma cells (ARH-77 cells) expressing little syndecan-1 readily form tumors, leading to hind limb paralysis and lytic bone disease. However, after the injection of syndecan-1–transfected ARH-77 cells, the development of disease-related morbidity and lytic bone disease is significantly inhibited. Taken together, our data demonstrate, both in vitro and in vivo, that syndecan-1 has a significant beneficial effect on the behavior of both myeloma and bone cells and therefore may represent one of the central molecules in the regulation of myeloma pathobiology.Keywords
This publication has 36 references indexed in Scilit:
- Regulated Shedding of Syndecan-1 and -4 Ectodomains by Thrombin and Growth Factor Receptor ActivationPublished by Elsevier ,1997
- Decorin-induced Growth Suppression Is Associated with Up-regulation of p21, an Inhibitor of Cyclin-dependent KinasesPublished by Elsevier ,1996
- A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1British Journal of Haematology, 1996
- Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence.Journal of Clinical Investigation, 1996
- The Role of Syndecan-1 in MalignanciesAnnals of Medicine, 1996
- Possible Regulation of FGF Activity by Syndecan, an Integral Membrane Heparan Sulfate ProteoglycanaAnnals of the New York Academy of Sciences, 1991
- Proteoglycans as modulators of growth factor activitiesCell, 1991
- B lymphocytes express and lose syndecan at specific stages of differentiation.Cell Regulation, 1989
- Cell surface proteoglycan expression correlates with epithelial-mesenchymal interaction during tooth morphogenesisDevelopmental Biology, 1988
- Heparan sulfate proteoglycans from mouse mammary epithelial cells: localization on the cell surface with a monoclonal antibody.The Journal of cell biology, 1985